Clinical trials: Hepatitis D, Chronic
Hepatitis C, Chronic
Evaluating Silymarin for Chronic Hepatitis C
To investigate the effect of silymarin, derived from the milk thistle plant, Silybum marianum, in preventing and reversing the complications of chronic infection with hepatitis C virus and/or clearing hepatitis C infections.
- Trial name
- NCT00030030
- Testing
- Silymarin (milk thistle)
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hepatitis C, Chronic
IdB 1016 Treatment for Hepatitis C Disease
This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies.
- Trial name
- NCT00055445
- Testing
- IdB 1016
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hepatitis B, Chronic
KRN7000 in Chronic Hepatitis B
The purpose of this trial is to determine the safety, tolerability and effectiveness of KRN7000 for chronic hepatitis B infection.
- Trial name
- NCT00363155
- Testing
- KRN7000
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis C
Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection
Phase I/II trial of KRN7000 in patients with chronic hepatitis C. Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer.
- Trial name
- NCT00352235
- Testing
- KRN7000
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis C
Continuing Treatment With Pegasys and Copegus
Primary objective is to measure sustained viral response given to continuation or prolongation of combined Pegasys\&Copegus treatment Secondary objective is to measure histological response given to continuation or prolongation…
- Trial name
- NCT00336518
- Testing
- peginterferon alfa-2a, ribavirin
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Májbetegekért Alapítvány
Chronic Hepatitis B, Chronic Hepatitis D
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D…
- Trial name
- NCT00117533
- Testing
- pegylated IFN alfa-2b plus ribavirin
- Where
- 2 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis C
Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects
The purpose of this study is to compare PEG-interferon alfa-2b and two different doses of rivavirin for the treatment of chronic hepatitis C in previously untreated adult subjects
- Trial name
- NCT00299936
- Testing
- Ribavirin, PEG-Intron
- Volunteers
- 5,000 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Hepatitis C Virus Infection
Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT
A relatively large proportion of patients with chronic HCV infection have normal or mildly elevated ALT. Many of these patients are not being treated, and are not being sent for a liver biopsy.
- Trial name
- NCT00294489
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Chronic Hepatitis B
Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B
Hepatitis B virus (HBV) causes a wide spectrum of liver diseases, such as fulminant or acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT00275938
- Testing
- interferon alpha 2b plus ribavirin
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C Virus Chronic Infection
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
We hypothesized that pretreatment nonresponder and responder liver tissue would show consistent differences in gene expression levels and that these differences could be used to predict treatment outcomes and this can obviate the…
- Trial name
- NCT00272389
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Hadassah Medical Organization
Chronic Hepatitis C, HCV Genotype 1
Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication
Open-label, single centre study evaluating efficacy and viral kinetics of combination PEG-IFNa2a and Ribavirin treatment on CHC genotype 1 patients, administered until viral clearance demonstrated between 4 - 12 weeks, then…
- Trial name
- NCT00152581
- Testing
- Pegylated interferon-alfa2a (Pegasys); ribavirin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College London Hospitals
Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections
HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy
Objectives: Primary To evaluate the safety, tolerability, and efficacy of Peginterferon a-2a plus Ribavirin for the treatment of chronic hepatitis C (CHC) infection in persons co-infected with human immunodeficiency virus (HIV)…
- Trial name
- NCT00215839
- Testing
- Peginterferon a-2a plus Ribavirin
- Where
- United States
- Sponsor
- Hepatitis Resource Network
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network
Chronic Hepatitis C Virus Infection
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy
HRN-003 STUDY SYNOPSIS OBJECTIVE: To compare the Sustained Virologic Response (SVR) of PEGIntron plus ribavirin among patients receiving a fixed dose of PEGIntron versus weighted-adjusted dosing.
- Trial name
- NCT00215865
- Testing
- PEGIntron plus ribavirin
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Hepatitis Resource Network
Chronic Hepatitis C
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.
- Trial name
- NCT00209755
- Testing
- therapeutic drug monitoring of ribavirin and dose adaptation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital A Michallon
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00157534
- Testing
- Celgosivir
- Volunteers
- 43 people
- Sponsor
- BioWest Therapeutics Inc
Chronic Hepatitis C
Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients
Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C
- Trial name
- NCT00146016
- Testing
- Amantadine
- Where
- Netherlands
- Volunteers
- 390 people
- Sponsor
- UMC Utrecht
Hepatitis C, Chronic
Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)
This was a randomized, multi-center, partially placebo-controlled Phase IV study to compare the efficacy and tolerability of a 48-week combined therapy with pegylated interferon alpha-2a, ribavirin and amantadine sulphate versus…
- Trial name
- NCT00127777
- Testing
- Amantadine sulphate (in addition to standard treatment)
- Volunteers
- 700 people
- Sponsor
- University Hospital, Saarland
Hepatitis C, Chronic
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.
- Trial name
- NCT00122629
- Testing
- peg-interferon alfa-2b, ribavirin, amantadine
- Where
- France
- Volunteers
- 405 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis